TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Meet 4 of 6 criteria of 2002 American-European Consensus Group (AECG) criteria for Primary Sjogren's Syndrome~2. Presence of anti Ro autoantibodies~3. Presence of interferon signature~Exclusion Criteria:~1. Use fo hydroxychloroquine within 30 days of baseline~2. Use of cyclophosphamide within 180 days of baseline~3. Use of oral corticosteroids greater than 10 mg/day~4. Known IgG4-related disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- RSLV-132 (Type: ACTIVE_COMPARATOR): Experimental drug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Sevoflurane and Desflurane on Treg

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients receiving 1st living donor kidney transplantation~Exclusion Criteria:~* Hyperacute graft rejection~* Pre-existing autoimmune or immunodeficiency diseases in recipients~* Receiving blood product during 24-h perioperative period~* Patient refuse to participate this study at any time point

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sevoflurane (Type: ACTIVE_COMPARATOR): In sevoflurane arm (n=20) at the beginning after successful intubation, 2 L/min nitric oxide (N2O), 2 L/min O2 , and 2% to 2.5% sevoflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 minimal alveolar concentration (MAC) of sevoflurane in 50% O2 and 50% N2O.
- Desflurane (Type: EXPERIMENTAL): In desflurane arm (n=20) at the beginning after successful intubation, 2 L/min N2O, 2 L/min O2, and 6% to 8% desflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 MAC of desflurane in 50% O2 and 50% N2O.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: EARLY_PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
* Inclusion Criteria:~  * at least 5 yrs since their last menses~ * Follicle Stimulating Hormone (FSH) \> 20 IU/L~* Exclusion Criteria:~  * Abnormality in any of the screening laboratory studies~ * Presence of significant liver or renal disease~ * Malignancy (including myeloma)~ * Malabsorption~ * Diabetes~ * Hypoparathyroidism~ * Hyperparathyroidism~ * Acromegaly~ * Cushing's syndrome~ * Hypopituitarism~ * Severe chronic obstructive pulmonary disease~ * Undergoing treatment with any medications that affect bone turnover, including the following:~* adrenocorticosteroids (\> 3 months at any time or \> 10 days within the previous yr)~* anticonvulsant therapy (within the previous year)~* pharmacological doses of thyroid hormone (causing decline of thyroid stimulating hormone below normal)~* calcium supplementation of \> 1200 mg/d (within the preceding 3 months)~* bisphosphonates (within the past 3 yrs)~* denosumab~* estrogen (E) therapy within the past year~* treatment with a selective E receptor modulator within the past year~* teriparatide within the past yr~* anti-hypertensive therapy~  * Clinical history of osteoporotic fracture (vertebral, hip, or distal forearm~ * Recent (within the past 6 months) fracture~ * Serum 25-hydroxyvitamin D levels of \< 20 ng/ml~ * Resting blood pressure \>140/90 mm Hg or those with hypotension (systolic blood pressure \<110 mm Hg), heart rate \< 60 bpm~ * History of asthma

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): Sugar pill 2/day for 20 weeks; The once daily groups will receive a placebo as the second dose
- Atenolol (Type: ACTIVE_COMPARATOR): Atenolol 50 mg 1/day for 20 weeks
- Nebivolol (Type: ACTIVE_COMPARATOR): Nebivolol 5 mg/day for 20 weeks
- Propranolol 40 mg (Type: ACTIVE_COMPARATOR): Propranolol 20 mg bid for 20 weeks
- Propranolol 80 mg (Type: ACTIVE_COMPARATOR): Propranolol 40 mg bid for 20 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reconstruction of Monocytic Immunocompetence by Granulocyte-macrophage-colony Stimulating Factor (GM-CSF) in Patients With Severe Sepsis and Septic Shock

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Severe sepsis or septic shock,~* Presence of infection,~* 2 SIRS criteria,~* Acute organ dysfunction,~* Immunoparalysis,~* Informed consent~Exclusion Criteria:~* Pregnancy,~* Known allergies to study medication or components,~* Moribound patient,~* Autoimmune disease,~* HIV-infection,~* Acute MI or pulmonary embolism,~* Cpr during last 72 hours,~* Patients who participate in a different clinical study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Verum (Type: EXPERIMENTAL): GM-CSF therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria :~* Two month old infant (50 to 71 days old) on the day of inclusion, of either gender.~* Born at full term of pregnancy (\>= 37 weeks) and with a birth weight \>= 2.5 kg.~* Hepatitis B vaccination since birth.~* Informed consent form signed by one parent/legally acceptable representative and an independent witness if the parent/legally acceptable representative is illiterate.~* Able to attend all scheduled visits and to comply with all trial procedures.~Exclusion Criteria :~* Participation in another clinical trial in the 4 weeks preceding the first trial vaccination.~* Planned participation in another clinical trial during the present trial period.~* Systemic hypersensitivity to any of the vaccine components or history of a life threatening reaction to the trial vaccine or a vaccine containing the same substances.~* Congenital or acquired immunodeficiency, or immunosuppressive therapy such as long-term systemic corticosteroid therapy.~* Chronic illness at a stage that could interfere with trial conduct or completion.~* Blood or blood-derived products received since birth.~* Any vaccination in the 4 weeks preceding the first trial vaccination.~* Any planned vaccination (except trial vaccinations) during the trial.~* Documented history of pertussis, T, D, polio, Hib, hepatitis B or Streptococcus pneumoniae infection(s) (confirmed either clinically, serologically, or microbiologically).~* Previous vaccination against pertussis, tetanus, diphtheria, poliomyelitis, Haemophilus influenzae type b infection(s) or Streptococcus pneumoniae.~* Known personal or maternal history of HIV, HB (HbsAg carrier) or hepatitis C seropositivity.~* Known thrombocytopenia or bleeding disorder contraindicating IM vaccination.~* History of seizures.~* Febrile (rectal equivalent temperature \>= 38.0°C) or acute illness on the day of inclusion.

- Gender: ALL
- Minimum Age: 50 Days
- Maximum Age: 71 Days
- Healthy Volunteers: t

Study Arms:
- Group 1: DTaP IPV Hep B PRP T + Prevnar™ (Type: EXPERIMENTAL): None
- Group 2: Infanrix hexa™ + Prevnar™ (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ConsultaTM CRT-D Clinical Evaluation Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have an indication for a defibrillator.~* Patients who are optimally treated with medication.~* Patients who are New York Heart Association (NYHA) Class III or IV~Exclusion Criteria:~* Patients with a life expectancy less than the duration of the study.~* Patients with medical conditions that preclude the testing required for all patients by the study protocol or that otherwise limit study participation required for all patients.~* Patients with mechanical tricuspid heart valves.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Implantation of Consulta CRT-D (Type: EXPERIMENTAL): Patients have an implant attempt with a Bi-ventricular Implantable Cardioverter Defibrillator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Men and women age 35-75 who have evident CHD~Exclusion Criteria:~Known hypersensitivity to HMG CO-A reductase therapy, liver disease, evidence of secondary hyperlipidemia

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically-confirmed diagnosis of invasive breast cancer, previously untreated~* Patients must be postmenopausal~* Candidates for mastectomy or breast-conserving surgery~* Primary tumor of above 2 cm diameter, measured by imaging~* Clinical Stage M0~* WHO performance status ≤1~* Adequate bone marrow, liver, and renal function~Exclusion Criteria:~* Multicentric invasive tumors~* Bilateral or inflammatory breast cancer~* Receiving concomitant anti-cancer treatments such as chemotherapy~* Patients with an uncontrolled infection~* Patients with other concurrent severe and/or uncontrolled medical disease~Additional protocol-defined inclusion/exclusion criteria may apply.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RAD001 + letrozole 2.5mg (Type: EXPERIMENTAL): None
- Letrozole 2.5mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Galunisertib in Participants With Myelodysplastic Syndromes

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of MDS based on the World Health Organization (WHO) criteria~* Participants with 5q deletions are allowed only if they have failed or are intolerant of lenalidomide treatment~* Participants must have a Revised International Prognostic Scoring System (IPSS-R) category of very low-, low-, or intermediate-risk disease~* In the 8 weeks prior to registration, participants in phase 2 should have anemia with Hb ≤10.0 g/dL (based on the average of 2 baseline measurements and untransfused for at least 1 week) with or without red blood cell (RBC) transfusion dependence confirmed for a minimum of 8 weeks before enrollment~* For phase 3, participants should have anemia with RBC transfusion dependence confirmed within 8 weeks before enrollment~* Performance status ≤2 on the Eastern Cooperative Oncology Group (ECOG) scale~Exclusion Criteria:~* No history of moderate or severe cardiac disease~* No prior history of acute myeloid leukemia (AML)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase (ph) 2: Galunisertib + BSC (Type: EXPERIMENTAL): Ph 2. 150 milligrams Galunisertib given orally twice daily (BID) for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive best supportive care (BSC) according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit.
- Ph 3: Placebo + BSC (Type: PLACEBO_COMPARATOR): Placebo administered orally BID for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive BSC according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit. This arm is contingent on the data from the phase 2 arm.
- Ph 3: Galunisertib + BSC (Type: EXPERIMENTAL): 150 milligrams Galunisertib given orally twice daily (BID) for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive best supportive care (BSC) according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit. This arm is contingent on the data from the phase 2 arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Running Retraining to Minimize Braking Forces

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to commit to a 15-week half-marathon training program~* Have been running for at least 3 months prior to study commencement~* Have participated in 2 or less half-marathons previously~* Ability to run on a treadmill unaided~* Ability to travel to testing facility for running analysis pre- and post-training program as well as for gait retraining sessions~* Ability to understand written and spoken English~* Meet the screening requirements (display less than -0.27BW mean peak braking force at baseline/screening assessment)~Exclusion Criteria:~* Any lower extremity pathology in the previous 3 months or currently have pain in their lower back or lower extremities while running~* Have undergone hip, knee, or ankle joint surgery

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Real time biofeedback (Type: EXPERIMENTAL): Real-time visual biofeedback of braking forces during a treadmill run.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: STI571 ProspectIve RandomIzed Trial: SPIRIT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients over 18 years of age~* Patients with Bcr-Abl positive CML in chronic phase.~* Patients within 14 weeks of diagnosis and previously untreated for CML except for hydroxyurea and/or anagrelide.~* No evidence of extramedullary leukemic involvement, with the exception of hepatosplenomegaly~* ECOG performance score of 0-2~* acceptable hepatic, renal, and cardiac function~* Informed consent signed up~Exclusion Criteria:~* Depressive syndrome not controlled~* Uncontrolled medical illnesses.~* Women with childbearing potential and male patients who are unwilling or unable to use an adequate method to avoid pregancy for the entire period of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Imatinib mesylate 400 mg (Type: EXPERIMENTAL): None
- Imatinib mesylate 600 mg (Type: EXPERIMENTAL): None
- Imatinib mesylate 400 mg +Peg interferon (Type: EXPERIMENTAL): None
- Imatinib mesylate 400 mg +Cytarabine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: HRV Biofeedback in Pain Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* are a Veteran between age 18 or older~* have chronic, non-malignant, neuro-musculoskeletal pain~Exclusion Criteria:~* a history of arrhythmia requiring medication or hospitalization~* a pacemaker or automatic implantable cardioverter-defibrillator~* a history of ischemic heart disease, heart transplant, cardiovascular surgery within 1 year~* congestive heart failure~* uncontrolled hypertension~* an active prescription for certain heart medications~* a history of seizures or use of antiseizure or anticonvulsant medication~* moderate or severe head injury or stroke~* evidence of active substance abuse or dependence (alcohol or tobacco use is not be an exclusion, participants will be asked to provide information about these behaviors in the investigators' questionnaire)~* a history of bipolar, psychotic, panic or obsessive-compulsive disorder (note: depression is an exclusion)~* cognitive impairment (dementia), neurocognitive deficits, or a central nervous system or neurological disorder (e.g., Gulf War Syndrome)~* a current or pending worker compensation claim or personal injury litigation related to the participants' symptoms

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- active HRVB training (Type: EXPERIMENTAL): Heart rate variability biofeedback training
- sham HRVB training (Type: SHAM_COMPARATOR): passive relaxation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject provides written informed consent and is willing and able to comply with the protocol in the opinion of the Investigator.~* Subject is 18 to 75 years of age, inclusive.~* Subject has MDD (diagnosed by DSM-IV-TR, and confirmed by the Structured - Clinical Interview for DSM-IV Disorders - Clinical Trial version \[SCID-CT\]).~* Subject is currently experiencing a major depressive episode (diagnosed by DSM IV TR; at least 2 weeks in duration) AND two or three of the following manic symptoms occurring on most days over at least the last 2 weeks (confirmed by the SCID-CT modified for Study D1050304):~  * Elevated, expansive mood~ * Inflated self-esteem or grandiosity~ * More talkative than usual or pressure to keep talking~ * Flight of ideas or subjective experience that thoughts are racing~ * Increase in energy or goal-directed activity (either socially, at work or school, or sexually)~ * Increased or excessive involvement in activities that have a high potential for painful consequences (e.g., engaging in unrestrained buying sprees, sexual indiscretions, or foolish business investments)~ * Decreased need for sleep (feeling rested despite sleeping less than usual; to be contrasted from insomnia)~Exclusion Criteria:~* Subject has Axis I or Axis II diagnosis other than MDD that has been the primary focus of treatment within the 3 months prior to screening.~* Subject answers yes to Suicidal Ideation Item 4 or 5 on the C-SSRS (at time of evaluation) at screening or baseline visit.~* Subject has attempted suicide within the past 3 months.~* Subject has a lifetime history of any bipolar I manic or mixed manic episode.~* Subject has any abnormal laboratory parameter at screening that indicates a clinically significant medical condition as determined by the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Lurasidone (Type: EXPERIMENTAL): Lurasidone 20, 40 or 60 mg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete